Afrezza denied as not FDA-approved for this use by Humana?

Humana's specific coverage criteria for afrezza are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana May Issue a "Not FDA-Approved" Denial for Afrezza

This denial type is worth examining carefully, because Afrezza is FDA-approved — it received FDA approval for use in adults with diabetes. A "not FDA-approved" denial in this context usually means one of three things: (1) the claim was miscoded and the reviewer was unable to match it to the approved drug; (2) Humana is applying the denial to a specific use or patient population it believes falls outside the approved indication; or (3) the denial is administrative error.

Before appealing, confirm with the prescriber and pharmacy that the drug name, NDC code, and diagnosis code on the claim are accurate. A coding correction alone sometimes resolves this denial without a formal appeal.

## Why This Denial Is Appealable

If the claim is correctly coded, a "not FDA-approved" denial for an on-label use of an FDA-approved drug is directly contestable. Under ACA Section 2719 you have the right to internal appeal and independent external review by a federally accredited IRO. ERISA Section 503 applies to self-funded plans and guarantees access to the specific criteria underlying the denial. The external-review window is typically around four months from the final internal denial; expedited review (commonly 72 hours) is available when delay would seriously jeopardize health.

## Building the Appeal

1. Obtain the FDA approval documentation. The FDA-approved prescribing information (package insert) for Afrezza is publicly available. Include a copy with your appeal and highlight the approved indication that applies to your patient's diagnosis.

2. Confirm the claim codes are correct. Verify the NDC, HCPCS/CPT code, and ICD-10 diagnosis code with the pharmacy and prescriber. Attach a corrected claim if any code was wrong.

3. Request the specific basis for denial in writing. Ask Humana to identify exactly which FDA-approval criterion it believes is not met. The denial letter should contain this; if it does not, request it before filing the appeal so you can respond to the actual stated reason.

4. Address the denied indication directly. If Humana contends the use is off-label, the prescriber must explain in a medical-necessity letter why this use is consistent with the FDA-approved label and, where relevant, with applicable clinical guidelines from organizations such as the American Diabetes Association.

5. Map the prescribing information to the patient's clinical facts. Create a brief criteria-mapping document: left column = each relevant criterion from the FDA label; right column = the chart entry confirming the patient meets it.

## Key Documents

• Denial letter with the specific reason stated
• FDA prescribing information for Afrezza (highlight the approved indication)
• Corrected claim information if any code was in error
• Prescriber letter confirming on-label use and clinical rationale
• Relevant chart notes and diagnosis documentation
• Humana's applicable medical or coverage policy (request the version current at denial date)

## Timeline

• Internal appeal: Submit within the timeframe on the denial notice. Standard decisions typically within 30–60 days; expedited within 72 hours.
• External review: Request within approximately four months of the final internal denial. The IRO applies clinical and regulatory standards independently of Humana.